Economic burden following allogeneic hematopoietic stem cell transplant in patients with diffuse large B-cell lymphoma

References

• Lymphoma Research Foundation [Internet]. Diffuse Large B-Cell Lymphoma (DLBCL); 2016 [cited Dec 2016]. Available from: http://www.lymphoma.org/site/pp.asp?c=bkLTKaOQLmK8E&b=6300153
   Google Scholar
• World Health Organization (WHO) [Internet]. Diffuse large B-cell lymphoma (2014); 2016 [cited Dec 2016]. Available from: http://www.who.int/selection_medicines/committees/expert/20/applications/DiffuseLargeBCellLymphoma.pdf
   Google Scholar
• Link BK, Brooks J, Wright K, et al. Diffuse large B-cell lymphoma in the elderly: diffusion of treatment with rituximab and survival advances with and without anthracyclines. Leuk Lymphoma. 2011;52:994–1002.
   PubMed Web of Science ®Google Scholar
• Dabrowska-Iwanicka A, Walewski JA. Primary mediastinal large B-cell lymphoma. Curr Hematol Malig Rep. 2014;9:273–283.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Gascoyne RD. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood. 2015;125:22–32.
   PubMed Web of Science ®Google Scholar
• Caimi PF, Hill BT, Hsi ED, et al. Clinical approach to diffuse large B cell lymphoma. Blood Rev. 2016;30:477–491.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network [Internet]. NCCN Clinical Practice Guidelines in Oncology: diffuse Large B-Cell Lymphoma V.3. 2016; [cited Dec 2016]. Available from: https://www.nccn.org/
   Google Scholar
• Vose JM, Carter S, Burns LJ, et al. Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial. J Clin Oncol. 2013;31:1662–1668.
   PubMed Web of Science ®Google Scholar
• Caimi PF, William BM, Silva Rondon CH, et al. Comparison of 2 carmustine-containing regimens in the rituximab era: excellent outcomes even in poor-risk patients. Biol Blood Marrow Transplant. 2015;21:1926–1931.
   PubMed Web of Science ®Google Scholar
• Friedberg JW. Relapsed/refractory diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program. 2011;2011:498–505.
   PubMed Web of Science ®Google Scholar
• Papageorgiou SG, Cwynarski K, Kottaridis PD. The role of allogeneic haematopoietic progenitor cell transplantation in patients with diffuse large B-cell non-Hodgkin lymphomas (DLBCL). Bone Marrow Transplant. 2013;48:1271–1278.
   PubMedGoogle Scholar
• Chiapella A, Santambrogio E, Castellino A, et al. Integrating novel drugs to chemoimmunotherapy in diffuse large B-cell lymphoma. Expert Rev Hematol. 2017;10:697–705.
   PubMed Web of Science ®Google Scholar
• Klyuchnikov E, Bacher U, Kroll T, et al. Allogeneic hematopoietic cell transplantation for diffuse large B cell lymphoma: who, when and how? Bone Marrow Transplant. 2014;49:1–7.
   PubMed Web of Science ®Google Scholar
• Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354:1813–1826.
   PubMed Web of Science ®Google Scholar
• Lazarus HM, Zhang MJ, Carreras J, et al. A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR. Biol Blood Marrow Transplant. 2010; 16:35–45.
   PubMed Web of Science ®Google Scholar
• Milliman [Internet]. 2014 U.S. organ and tissue transplant cost estimates and discussion; 2014 [cited Dec 2016]. Available from: http://us.milliman.com/uploadedFiles/insight/Research/health-rr/1938HDP_20141230.pdf.
   Google Scholar
• Maziarz RT, Guérin A, Gauthier G, et al. Five-year direct costs of acute lymphoblastic leukemia pediatric patients undergoing allogeneic stem cell transplant. Int J Hematol Oncol. 2016;5:63–75.
   Google Scholar
• Preussler JM, Meyer CL, Mau LW, et al. Healthcare costs and utilization for patients age 50 to 64 years with acute myeloid leukemia treated with chemotherapy or with chemotherapy and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2017;23:1021–1028.
   PubMed Web of Science ®Google Scholar
• Khera N, Zeliadt SB, Lee SJ. Economics of hematopoietic cell transplantation. Blood. 2012;120:1545.
   PubMed Web of Science ®Google Scholar
• Preussler JM, Denzen EM, Majhail NS. Costs and cost-effectiveness of hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012;18:1620–1628.
   PubMed Web of Science ®Google Scholar
• Majhail NS, Mau LW, Denzen EM, et al. Costs of autologous and allogeneic hematopoietic cell transplantation in the United States: a study using a large national private claims database. Bone Marrow Transplant. 2013;48:294–300.
   PubMed Web of Science ®Google Scholar
• Gill S, June CH. Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies. Immunol Rev. 2015;263:68–89.
   PubMed Web of Science ®Google Scholar
• Preussler JM, Mau LW, Majhail NS, et al. Administrative claims data for economic analysis in hematopoietic cell transplantation: challenges and opportunities. Biol Blood Marrow Transplant. 2016;22:1738–1746.
   PubMed Web of Science ®Google Scholar
• Wingard JR, Majhail NS, Brazauskas R, et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol. 2011;29:2230–2239.
   PubMed Web of Science ®Google Scholar
• Kutikova L, Bowman L, Chang S, et al. Medical costs associated with non-Hodgkin’s lymphoma in the United States during the first two years of treatment. Leuk Lymphoma. 2006;47:1535–1544.
   PubMed Web of Science ®Google Scholar
• LeMaistre CF, Farnia S, Crawford S, et al. Standardization of terminology for episodes of hematopoietic stem cell patient transplant care. Biol Blood Marrow Transplant. 2013;19:851–857.
   PubMed Web of Science ®Google Scholar
• Radich JP, Gooley T, Sanders JE, et al. Second allogeneic transplantation after failure of first autologous transplantation. Biol Blood Marrow Transplant. 2000;6:272–279.
   PubMed Web of Science ®Google Scholar